Drug Database
Back to search

Netherlands· NL-c44dd19e131c

Elaprase 2 mg/ml, concentraat voor oplossing voor infusie 6 mg

A idursulfase product containing idursulfase, registered in Netherlands by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 14 of our 19 countries.

ATC A16AB09

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedElaprase 2 mg/ml, concentraat voor op…ATCA16AB09REGISTER NO.NL-c44dd19e131cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about idursulfaseAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Idursulfase is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB09 (idursulfase), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search idursulfase products by name

Idursulfase · ATC A16AB09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
IDURSULFASE
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Country
Netherlands (NL)
ATC code
A16AB09
ATC class
Idursulfase
Defined daily dose
5 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/06/365

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Idursulfase in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All idursulfase products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Elaprase
  • Liechtenstein · Elaprase
  • Norway · Elaprase

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/51c51c9a-5028-4684-82fc-d7e7d9990cb6
GET /v1/drugs/51c51c9a-5028-4684-82fc-d7e7d9990cb6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/elaprase-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Idursulfase",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp73034",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "POLYSORBAAT 20 (E 432)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "IDURSULFASE"
  ],
  "leaflet_url": null,
  "authorised_at": "2007/01/08",
  "procedure_number": "EMEA/H/C/000700",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/06/365",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about idursulfase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console